We synthesized the pure and indium-doped （IZO） ZnO films with a facile composition control spray pyrolysis route. The substrate temperature （Ts） and In-doping effects on the properties of as-grown films are inves-...We synthesized the pure and indium-doped （IZO） ZnO films with a facile composition control spray pyrolysis route. The substrate temperature （Ts） and In-doping effects on the properties of as-grown films are inves- tigated. The X-ray pattern confirms that the as-synthesized ZnO phase is grown along a （002） preferential plane. It is revealed that the crystalline structure is improved with a substrate temperature of 350 ℃ Moreover, the morphol- ogy of as-grown films, analyzed by AFM, shows nanostructures that have grown along the c-axis. The （3 ×3 μm2） area scanned AFM surface studies give the smooth film surface RMS 〈 40 nm. The UV-VIS-IR measurements reveal that the sprayed films are highly transparent in the visible and IR bands. The photoluminescence analysis shows that the strong blue and yellow luminescences of 2.11 and 2.81 eV are emitted from ZnO and IZO films with a slight shift in photon energy caused by In-doping. The band gap is a bit widened by In-doping, 3.21 eV （ZnO） and 3.31 eV （IZO） and the resistivity is reduced from 385 to 8Ω·m. An interesting result is the resistivity linear dependence on the substrate temperature of pure ZnO films.展开更多
Background:The present study aimed to develop a film-forming spray containing an epigallocatechin-3-gallate:Dexolve complex(FFS-EGCG:Dexolve)for site-specific treatment of throat cancer using newer excipients.Methods:...Background:The present study aimed to develop a film-forming spray containing an epigallocatechin-3-gallate:Dexolve complex(FFS-EGCG:Dexolve)for site-specific treatment of throat cancer using newer excipients.Methods:EGCG was used to treat throat cancer.The permeability of EGCG was improved by amalgamating with Kleptose/Dexolve.The screened complex was loaded into a film-forming spray solution.Quality by design(QbD)was utilized to develop FFS-EGCG:Dexolve,including HPMC E5 and Lycoat.A risk estimation matrix(REM)was utilized to scrutinize critical quality attributes(CQAs)and critical material attributes(CMAs),and a correlation was developed via a Box–Behnken design(BBD).FFS-EGCG:Dexolve was characterized for its in vitro and ex vivo characteristics.Results:EGCG:Dexolve(1:3)had excellent physical properties and 90.83±0.07%permeability.Through an REM,the film formation time and%EGCG released were screened as CQAs,whereas the amounts of HPMC E5,Lycoat,and Dexolve were chosen as CMAs.The amounts of HPMC E5,Lycoat,and Dexolve were considered crucial for designing FFS-EGCG:Dexolve,as determined by the BBD.FFS-EGCG:Dexolve formed instant films,covered a relatively large surface area,and had a long residence time,and controlled EGCG release was achieved for>6 h.The optimal batch comprising HPMC E5(11.98 mg),Lycoat(10.09 mg),and Dexolve(163.5 mg)had excellent spray characteristics,formed a film in 82 s,and released 85.39%EGCG in a controlled manner.Conclusion:A novel FFS-EGCG:Dexolve complex was developed to explore the novel excipients Lycoat,HPMC E5,and Dexolve.The throat-targeted film-forming spray developed a film quickly and released>85%EGCG in 6 h.The novel FFS-EGCG:Dexolve complex was formulated for site specificity and intelligent technologies to achieve better therapeutic efficacy.Patient-centric formulations have excellent industrial and social impacts.展开更多
基金a part of the CNEPRU project N° D01920120039 supported by the ministry of high teaching and scientific research MESRS www.mesrs.dz
文摘We synthesized the pure and indium-doped （IZO） ZnO films with a facile composition control spray pyrolysis route. The substrate temperature （Ts） and In-doping effects on the properties of as-grown films are inves- tigated. The X-ray pattern confirms that the as-synthesized ZnO phase is grown along a （002） preferential plane. It is revealed that the crystalline structure is improved with a substrate temperature of 350 ℃ Moreover, the morphol- ogy of as-grown films, analyzed by AFM, shows nanostructures that have grown along the c-axis. The （3 ×3 μm2） area scanned AFM surface studies give the smooth film surface RMS 〈 40 nm. The UV-VIS-IR measurements reveal that the sprayed films are highly transparent in the visible and IR bands. The photoluminescence analysis shows that the strong blue and yellow luminescences of 2.11 and 2.81 eV are emitted from ZnO and IZO films with a slight shift in photon energy caused by In-doping. The band gap is a bit widened by In-doping, 3.21 eV （ZnO） and 3.31 eV （IZO） and the resistivity is reduced from 385 to 8Ω·m. An interesting result is the resistivity linear dependence on the substrate temperature of pure ZnO films.
文摘Background:The present study aimed to develop a film-forming spray containing an epigallocatechin-3-gallate:Dexolve complex(FFS-EGCG:Dexolve)for site-specific treatment of throat cancer using newer excipients.Methods:EGCG was used to treat throat cancer.The permeability of EGCG was improved by amalgamating with Kleptose/Dexolve.The screened complex was loaded into a film-forming spray solution.Quality by design(QbD)was utilized to develop FFS-EGCG:Dexolve,including HPMC E5 and Lycoat.A risk estimation matrix(REM)was utilized to scrutinize critical quality attributes(CQAs)and critical material attributes(CMAs),and a correlation was developed via a Box–Behnken design(BBD).FFS-EGCG:Dexolve was characterized for its in vitro and ex vivo characteristics.Results:EGCG:Dexolve(1:3)had excellent physical properties and 90.83±0.07%permeability.Through an REM,the film formation time and%EGCG released were screened as CQAs,whereas the amounts of HPMC E5,Lycoat,and Dexolve were chosen as CMAs.The amounts of HPMC E5,Lycoat,and Dexolve were considered crucial for designing FFS-EGCG:Dexolve,as determined by the BBD.FFS-EGCG:Dexolve formed instant films,covered a relatively large surface area,and had a long residence time,and controlled EGCG release was achieved for>6 h.The optimal batch comprising HPMC E5(11.98 mg),Lycoat(10.09 mg),and Dexolve(163.5 mg)had excellent spray characteristics,formed a film in 82 s,and released 85.39%EGCG in a controlled manner.Conclusion:A novel FFS-EGCG:Dexolve complex was developed to explore the novel excipients Lycoat,HPMC E5,and Dexolve.The throat-targeted film-forming spray developed a film quickly and released>85%EGCG in 6 h.The novel FFS-EGCG:Dexolve complex was formulated for site specificity and intelligent technologies to achieve better therapeutic efficacy.Patient-centric formulations have excellent industrial and social impacts.
